RAPP Rapport Therapeutics, Inc.

Nasdaq www.rapportrx.com


$ 28.48 $ 0.08 (0.28 %)    

Wednesday, 29-Oct-2025 09:58:36 EDT
QQQ $ 636.43 $ 0.99 (0.16 %)
DIA $ 479.58 $ 0.97 (0.2 %)
SPY $ 689.14 $ 0.39 (0.06 %)
TLT $ 91.81 $ -0.06 (-0.07 %)
GLD $ 369.52 $ -0.16 (-0.04 %)
$ 28.96
$ 29.04
$ 28.27 x 100
$ 28.63 x 105
$ 29.04 - $ 29.21
$ 6.43 - $ 42.27
438,685
na
1.06B
$ 1.51
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-11-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Truist Securities analyst Joon Lee initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces ...

Core News & Articles

Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company d...

 rapport-reports-promising-epilepsy-study-outcomes-plans-phase-3-trials-next-year

Rapport Therapeutics' RAP-219 cut seizures significantly in a Phase 2a trial, with strong results and a favorable safety pr...

Core News & Articles

HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price ta...

Core News & Articles

RAPP: 176% | Rapport Therapeutics' Phase 2a Trial Of RAP-219 In Drug-Resistant Focal Onset Seizures Met Its Primary Endpoin...

Core News & Articles

Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients a...

Core News & Articles

Rapport Therapeutics, Inc.

Core News & Articles

Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of ...

Core News & Articles

HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION